TNF antagonists characteristics
| Infliximab | Etanercept | Adalimumab | |
|---|---|---|---|
| Structure | Chimeric mAb | TNF IgG1 | Human mAb |
| Fusion protein | |||
| Binding target | TNF | TNF, lymphotoxin | TNF |
| Binding affinity | 1.8×109 | 1010 | 2.3×1010 |
| Half life (days) | 8–9.5 | 4–5 | 12–14 |
| In vitro cell lysis | + | − | + |
| Dose | Every 60 days | Every 3–4 days | Every 7–14 days |
| Efficacy/Crohn’s disease | + | − | ? |